Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.
Por:
Ruiz-Argüello MB, Maguregui A, Ruiz Del Agua A, Pascual-Salcedo D, Martínez-Feito A, Jurado T, Plasencia C, Balsa A, Llinares-Tello F, Rosas J, Torres N, Martínez A and Nagore D
Publicada:
1 sep 2016
Ahead of Print:
10 mar 2016
Resumen:
The aim of this study was to determine whether antibodies to infliximab (IFX) in Remicade-treated patients cross-react with the biosimilar CT-P13.
Filiaciones:
Ruiz-Argüello MB:
R&D Department, Progenika-Grifols, Derio, Spain
Maguregui A:
R&D Department, Progenika-Grifols, Derio, Spain
Ruiz Del Agua A:
R&D Department, Progenika-Grifols, Derio, Spain
Pascual-Salcedo D:
Immunology Unit, La Paz University Hospital, Madrid, Spain
Martínez-Feito A:
Immunology Unit, La Paz University Hospital-Idipaz, Madrid, Spain
Jurado T:
Rheumatology Department, La Paz University Hospital, Madrid, Spain
Plasencia C:
Rheumatology Department, La Paz University Hospital, Madrid, Spain
Balsa A:
Rheumatology Department, La Paz University Hospital, Madrid, Spain
:
Clinical Analysis, Hospital Marina Baixa, Villajoyosa, Spain
Rosas J:
Rheumatology Department, Hospital Marina Baixa, Villajoyosa, Spain
Torres N:
R&D Department, Progenika-Grifols, Derio, Spain
Martínez A:
R&D Department, Progenika-Grifols, Derio, Spain
Nagore D:
R&D Department, Progenika-Grifols, Derio, Spain
Open Access
|